This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ASCO '12: Bristol Drug Unlocks Immune System to Target Cancer

CHICAGO ( TheStreet) - -An experimental drug from Bristol-Myers Squibb (BMY - Get Report) that helps the immune system attack cancer cells was able to shrink tumors in patients with melanoma, kidney and non-small cell lung cancers, according to results from an early-stage study being presented Saturday today at the American Society of Clinical Oncology (ASCO) annual meeting.

The promising Bristol drug, BMS-936658, follows in the footsteps of Yervoy, another Bristol drug that was approved last year to treat melanoma and which also harnesses the power of a patient's immune system to fight cancer.

Bristol is accelerating development of '658 and will push the drug into pivotal, phase III studies in lung cancer, melanoma and kidney cancer, based in part of the data presented at this year's ASCO meeting.

The phase I study enrolled patients diagnosed with solid tumors that had progressed despite treatment with currently approved therapies. After treatment with Bristol's '658, responses (partial tumor shrinkage) were observed in patients wtih melanoma, kidney cancer patients and lung cancer. Updated data will be presented at ASCO Saturday afternoon.

Bristol's '658 is an antibody that targets a cellular signal known as PD-1 which cancer cells turn on to prevent attacks from T-cells, the white blood cells that help fight infection and cancer. By blocking or turning off the PD-1 pathway, Bristol's '658 appears to re-activate the immune system and allows it to fight tumor cells.

Merck (MRK - Get Report), Roche (RHHBY) and GlaxoSmithKline (GSK - Get Report) are also developing their own PD-1 inhibitors as potential cancer therapies.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
RHHBY $36.04 0.00%
BMY $64.66 0.00%
GSK $45.97 0.00%
MRK $59.86 0.00%
AAPL $128.95 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs